"Disease-Free Survival" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Descriptor ID |
D018572
|
MeSH Number(s) |
E01.789.200 E05.318.740.998.300 N05.715.360.750.795.300 N06.850.520.830.998.300
|
Concept/Terms |
Disease-Free Survival- Disease-Free Survival
- Disease Free Survival
- Event-Free Survival
- Event Free Survival
- Event-Free Survivals
- Survival, Event-Free
- Survivals, Event-Free
- Survival, Disease-Free
- Disease-Free Survivals
- Survival, Disease Free
- Survivals, Disease-Free
Progression-Free Survival- Progression-Free Survival
- Progression Free Survival
- Progression-Free Survivals
- Survival, Progression-Free
- Survivals, Progression-Free
|
Below are MeSH descriptors whose meaning is more general than "Disease-Free Survival".
Below are MeSH descriptors whose meaning is more specific than "Disease-Free Survival".
This graph shows the total number of publications written about "Disease-Free Survival" by people in this website by year, and whether "Disease-Free Survival" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 2 | 2 |
1997 | 0 | 1 | 1 |
1999 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2001 | 0 | 2 | 2 |
2002 | 0 | 1 | 1 |
2003 | 0 | 4 | 4 |
2004 | 0 | 4 | 4 |
2005 | 0 | 1 | 1 |
2006 | 0 | 1 | 1 |
2007 | 0 | 2 | 2 |
2008 | 0 | 3 | 3 |
2009 | 0 | 6 | 6 |
2010 | 0 | 11 | 11 |
2011 | 0 | 8 | 8 |
2012 | 0 | 6 | 6 |
2013 | 0 | 3 | 3 |
2014 | 0 | 8 | 8 |
2015 | 0 | 13 | 13 |
2016 | 1 | 6 | 7 |
2017 | 0 | 14 | 14 |
2018 | 1 | 5 | 6 |
2019 | 0 | 5 | 5 |
2020 | 0 | 4 | 4 |
2021 | 0 | 6 | 6 |
2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Disease-Free Survival" by people in Profiles.
-
Postibrutinib relapse outcomes for patients with marginal zone lymphoma. Blood Adv. 2023 01 10; 7(1):88-91.
-
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood Adv. 2021 07 27; 5(14):2852-2862.
-
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica. 2021 07 01; 106(7):1932-1942.
-
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. Eur J Haematol. 2021 Sep; 107(3):301-310.
-
Development of New-Onset or Progressive Atrial Fibrillation in Patients With Permanent HIS Bundle Pacing Versus Right Ventricular Pacing: Results From the RUSH HBP Registry. J Am Heart Assoc. 2020 11 17; 9(22):e018478.
-
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020 10; 191(1):44-51.
-
National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress? J Clin Endocrinol Metab. 2019 12 01; 104(12):5948-5956.
-
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clin Cancer Res. 2019 01 01; 25(1):64-72.
-
Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy. Expert Rev Hematol. 2018 07; 11(7):577-586.
-
Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer. 2018 06 15; 124(12):2541-2551.